Log on / register
Feedback | Support | My details
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage.
Wilcock DM, Rojiani A, Rosenthal A, Subbarao S, Freeman MJ, Gordon MN, Morgan D
J Neuroinflammation 2004 Dec 8, 1:24
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

PubMed Central articles that cite the above article:

1.
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model.
Levites Y, Das P, Price RW, Rochette MJ, Kostura LA, McGowan EM, Murphy MP, Golde TE
J Clin Invest 2006 Jan, 116:193-201
 [PubMed Central] [PubMed] [Related articles]
2.
Amyloid-beta peptide remnants in AN-1792-immunized Alzheimer's disease patients: a biochemical analysis.
Patton RL, Kalback WM, Esh CL, Kokjohn TA, Van Vickle GD, Luehrs DC, Kuo YM, Lopez J, Brune D, Ferrer I, Masliah E, Newel AJ, Beach TG, Castaño EM, Roher AE
Am J Pathol 2006 Sep, 169:1048-63
 [PubMed Central] [PubMed] [Related articles]
3.
Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages.
Asuni AA, Boutajangout A, Scholtzova H, Knudsen E, Li YS, Quartermain D, Frangione B, Wisniewski T, Sigurdsson EM
Eur J Neurosci 2006 Nov, 24:2530-42
 [PubMed Central] [PubMed] [Related articles]
4.
Transcutaneous beta-amyloid immunization reduces cerebral beta-amyloid deposits without T cell infiltration and microhemorrhage.
Nikolic WV, Bai Y, Obregon D, Hou H, Mori T, Zeng J, Ehrhart J, Shytle RD, Giunta B, Morgan D, Town T, Tan J
Proc Natl Acad Sci U S A 2007 Feb 13, 104:2507-12
 [PubMed Central] [PubMed] [Related articles]
5.
Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.
Petrushina I, Ghochikyan A, Mktrichyan M, Mamikonyan G, Movsesyan N, Davtyan H, Patel A, Head E, Cribbs DH, Agadjanyan MG
J Neurosci 2007 Nov 14, 27:12721-31
 [PubMed Central] [PubMed] [Related articles]
6.
Catalytic antibodies to amyloid beta peptide in defense against Alzheimer disease.
Taguchi H, Planque S, Nishiyama Y, Szabo P, Weksler ME, Friedland RP, Paul S
Autoimmun Rev 2008 May, 7:391-7
 [PubMed Central] [PubMed] [Related articles]
7.
Nasal inoculation of an adenovirus vector encoding 11 tandem repeats of Abeta1-6 upregulates IL-10 expression and reduces amyloid load in a Mo/Hu APPswe PS1dE9 mouse model of Alzheimer's disease.
Kim HD, Tahara K, Maxwell JA, Lalonde R, Fukuiwa T, Fujihashi K, Van Kampen KR, Kong FK, Tang DC, Fukuchi K
J Gene Med 2007 Feb, 9:88-98
 [PubMed Central] [PubMed] [Related articles]
8.
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials.
Wilcock DM, Colton CA
J Alzheimers Dis 2008 Dec, 15:555-69
 [PubMed Central] [PubMed] [Related articles]
9.
Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2.
Wilcock DM, Lewis MR, Van Nostrand WE, Davis J, Previti ML, Gharkholonarehe N, Vitek MP, Colton CA
J Neurosci 2008 Feb 13, 28:1537-45
 [PubMed Central] [PubMed] [Related articles]
10.
Intracerebroventricular amyloid-beta antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice.
Thakker DR, Weatherspoon MR, Harrison J, Keene TE, Lane DS, Kaemmerer WF, Stewart GR, Shafer LL
Proc Natl Acad Sci U S A 2009 Mar 17, 106:4501-6
 [PubMed Central] [PubMed] [Related articles]
11.
Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice.
Wilcock DM, Colton CA
CNS Neurol Disord Drug Targets 2009 Mar, 8:50-64
 [PubMed Central] [PubMed] [Related articles]
12.
Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology.
Scholtzova H, Kascsak RJ, Bates KA, Boutajangout A, Kerr DJ, Meeker HC, Mehta PD, Spinner DS, Wisniewski T
J Neurosci 2009 Feb 11, 29:1846-54
 [PubMed Central] [PubMed] [Related articles]
13.
Alternative Abeta immunotherapy approaches for Alzheimer's disease.
Town T
CNS Neurol Disord Drug Targets 2009 Apr, 8:114-27
 [PubMed Central] [PubMed] [Related articles]
14.
CD40L disruption enhances Abeta vaccine-mediated reduction of cerebral amyloidosis while minimizing cerebral amyloid angiopathy and inflammation.
Obregon D, Hou H, Bai Y, Nikolic WV, Mori T, Luo D, Zeng J, Ehrhart J, Fernandez F, Morgan D, Giunta B, Town T, Tan J
Neurobiol Dis 2008 Feb, 29:336-53
 [PubMed Central] [PubMed] [Related articles]
15.
Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice.
Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, Bacskai BJ, Holtzman DM
J Neurosci 2008 Dec 24, 28:14156-64
 [PubMed Central] [PubMed] [Related articles]
16.
Chaperone signalling complexes in Alzheimer's disease.
Koren J, Jinwal UK, Lee DC, Jones JR, Shults CL, Johnson AG, Anderson LJ, Dickey CA
J Cell Mol Med 2009 Apr, 13:619-30
 [PubMed Central] [PubMed] [Related articles]

This article is also cited by 7 articles in BioMed Central

printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.